A0200000
Acetylsalicylic acid
European Pharmacopoeia (EP) Reference Standard
Sinonimo/i:
2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Formula condensata:
2-(CH3CO2)C6H4CO2H
Numero CAS:
Peso molecolare:
180.16
Beilstein:
779271
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24
Prodotti consigliati
Grado
pharmaceutical primary standard
Famiglia di API
aspirin
Produttore/marchio commerciale
EDQM
Punto di fusione
134-136 °C (lit.)
applicazioni
pharmaceutical (small molecule)
Formato
neat
Temperatura di conservazione
2-8°C
Stringa SMILE
CC(=O)Oc1ccccc1C(O)=O
InChI
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
Informazioni sul gene
human ... PTGS1(5742) , PTGS2(5743)
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Descrizione generale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Applicazioni
Acetylsalicylic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Azioni biochim/fisiol
Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.
Confezionamento
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Altre note
Sales restrictions may apply.
Prodotti correlati
N° Catalogo
Descrizione
Determinazione del prezzo
Avvertenze
Warning
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Acute Tox. 4 Oral
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 1
Punto d’infiammabilità (°F)
482.0 °F
Punto d’infiammabilità (°C)
250 °C
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.
Se ti serve aiuto, non esitare a contattarci Servizio Clienti
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
Gwen M C Masclee et al.
Gastroenterology, 147(4), 784-792 (2014-06-18)
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.